Comparison of clinical-metabolic monitoring and outcomes and coronary risk status in people with type 2 diabetes from Australia, France and Latin America☆
To access this article, please choose from the options below
☆ Source of financial support: The QUALIDIAB project was sponsored by the Declaration of the Americas (DOTA), with funds from Becton Dickinson and Company, Eli Lilly and Company, LifeScan Inc, Novo Nordisk A/S, and Roche Diagnostics. ANDIAB was supported by Servier Laboratories and the Australian Government Department of Health and Ageing.
PII: S0168-8227(09)00549-X
doi:10.1016/j.diabres.2009.12.024
© 2010 Elsevier Ireland Ltd. All rights reserved.
Refers to erratum:
- Erratum to “Comparison of clinical-metabolic monitoring and outcomes and coronary risk status in people with type 2 diabetes from Australia, France and Latin America” [Diabetes Research and Clinical Practice 2010;88:7–13] , 12 July 2010
